[Click eStock] "L&K Bio, Scaling Up in Earnest"

On December 2, KB Securities analyzed that L&K Bio is now actively expanding its business scale.

Kim Hyungyeom, a researcher at KB Securities, stated, “On July 9, L&K Bio obtained approval from the U.S. Food and Drug Administration (FDA) for its spinal implant 'BluEx-TM.' This has established an important foundation for targeting the U.S. market.”

He added, “The key point is that the new version of the existing product 'PathLoc-TM' incorporates the advanced surface treatment technology of the 'BluEx' series, which enhances bone adhesion. Based on this, the company has laid the groundwork for a joint marketing strategy with its U.S. partner, targeting the entire U.S. market.”

He went on to say, “We expect the exclusive distribution agreement for the U.S. market to be fully implemented. The global spinal implant market is currently undergoing a reshuffling of rankings through mergers and acquisitions (M&A).” He also emphasized, “Overseas partners are now in urgent need of increasing sales and diversifying their product portfolios, and L&K Bio’s 'BluEx' series can meet these client needs.”

Kim also noted, “Attention should be paid to the high-profit growth of the new thoracic product 'CastleLoc Pectus.' After FDA approval, the company is targeting 30 client hospitals by the end of next year.” He continued, “Since direct supply is possible rather than through partners, profitability is high, making this a sufficient future growth engine.”

This content was produced with the assistance of AI translation services.